{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-22-000026","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.387722+00:00","generated_at":"2026-06-24T04:41:51.839559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex Q2 product revenue $2.20B (+22% YoY); raises FY2022 guidance to $8.6-$8.8B","bullets":["Product revenues $2.20B, up 22% YoY; TRIKAFTA/KAFTRIO contributed $1.893B.","GAAP diluted EPS $3.13; non-GAAP diluted EPS $3.60.","Raised full-year 2022 product revenue guidance to $8.6-$8.8B from prior $8.4-$8.6B.","Clinical updates: exa-cel (sickle cell/beta thalassemia) and VX-880 (type 1 diabetes) data demonstrate transformative potential."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-22-000026","json":"https://secwatch.observer/filing/0000875320-22-000026.json","markdown":"https://secwatch.observer/filing/0000875320-22-000026.md","text":"https://secwatch.observer/filing/0000875320-22-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000026/0000875320-22-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000026/vrtx-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:41:51.839559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}